CCM
BBIO icon

Cinctive Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Cinctive Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-145,728
Closed -$10.8M – 429
2026
Q1 		$10.8M Buy
145,728
+75,553
+108% +$5.48M 0.71% 30
2025
Q4 		$5.37M Sell
70,175
-25,497
-27% -$1.67M 0.29% 99
2025
Q3 		$4.97M Sell
95,672
-98,688
-51% -$4.81M 0.24% 137
2025
Q2 		$8.39M Buy
+194,360
New +$7.07M 0.44% 68
2025
Q1 		– Sell
-114,202
Closed -$3.13M – 324
2024
Q4 		$3.13M Buy
+114,202
New +$2.95M 0.16% 183
2021
Q4 		– Sell
-10,000
Closed -$469K – 540
2021
Q3 		$469K Buy
+10,000
New +$536K 0.02% 461

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Cinctive Capital Management's BBIO Position: Q2 2026 in Review

Cinctive Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 145,728 shares — an estimated $10.8M sold.

Cinctive Capital Management first reported a position in BBIO in Q3 2021 and held it in 6 quarters. The position peaked at $10.8M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Cinctive Capital Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 145,728 BridgeBio Pharma shares in Q2 2026, an estimated $10.8M.
  • Cinctive Capital Management first reported a position in BridgeBio Pharma in Q3 2021 and held it in 6 quarters.
  • Cinctive Capital Management's BridgeBio Pharma position peaked at $10.8M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.